Ozempic Across the Board: New Data Shows GLP-1 Drugs Cut SUD Risk Across Five Substance Classes

The hypothesis started as a side effect. Patients who were prescribed GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide — for weight loss or Type 2 diabetes were telling their doctors that they had also stopped drinking, or smoking, or craving the substances they’d struggled with for years. The clinical community filed these anecdotes under “interesting but uncontrolled.” Then the studies started coming in.

A major analysis published this month, drawing on data from researchers at Washington University School of Medicine and NIH-affiliated investigators, found that GLP-1 receptor agonist use was associated with statistically significant reductions in substance use disorder risk across five substance classes: alcohol, nicotine, cannabis, cocaine, and opioids. Across a three-year follow-up period, patients on GLP-1 medications showed a 30% reduction in emergency department visits, a 25% reduction in hospitalizations, a 40% reduction in overdose events, and a 50% reduction in drug-related deaths compared to matched controls. Among patients with alcohol use disorder specifically, those treated with semaglutide saw a 41.1% reduction in heavy drinking days.

These are substantial effect sizes. By comparison, naltrexone — the current gold standard for alcohol use disorder — produces roughly a 25% reduction in heavy drinking days in the best trials. The GLP-1 data, if it holds across prospective trials, would represent a meaningful expansion of the pharmacological toolkit for a field that has historically had very few effective medications.

What the Mechanism Might Be

GLP-1 (glucagon-like peptide-1) receptors are distributed throughout the brain, not just in the pancreas and gut where they’re most studied in the context of weight loss. The receptors are present in the nucleus accumbens, the ventral tegmental area, and the prefrontal cortex — the core circuitry of addiction. GLP-1 agonists appear to modulate dopamine signaling in these regions, blunting the reward response not just to food but to other substances that trigger dopamine release.

The theory is that GLP-1 drugs act as a kind of volume knob on reward salience. Food becomes less compelling, which is what makes them effective for weight loss. Substances become less compelling by a similar mechanism. The craving doesn’t disappear, but it arrives at a lower amplitude — something the person can override rather than something that overrides them.

This mechanism is not fully characterized. The research is observational in most cases, meaning it identifies associations rather than proving causation. Patients on GLP-1 drugs may differ from controls in ways that influence substance use independent of the medication. Randomized controlled trials specifically targeting SUD are underway but not yet complete.

What can be said is that the signal is consistent. It appears across different GLP-1 agonists. It appears across different substance classes. It appears in real-world data (clinical practice populations) and in more controlled analyses. That level of consistency across modalities is not nothing.

What the Rehab Industry Is Doing

STAT News reported this week that elite residential treatment facilities — programs that charge well above the insurance-reimbursed floor — have begun incorporating GLP-1 medications into their treatment protocols. The approach is not standard or regulated, and the physicians doing it are doing it off-label, drawing on the observational evidence and their clinical judgment rather than on FDA-approved protocols for SUD.

This is where the field almost always goes first: high-cost facilities with the resources and flexibility to experiment. The same pattern played out with ketamine for depression, with MDMA-assisted therapy for PTSD, with suboxone itself before the DATA 2000 waiver formalized office-based prescribing. The early adopters are almost never the patients with the most need. They are the patients with the most money.

The translation question — how and when GLP-1s become available for the full SUD treatment population, including the Medicaid-covered patients who make up the majority of people seeking treatment for opioid and alcohol use disorder — will depend on FDA labeling, on payer coverage decisions, and on how quickly the prospective RCT evidence matures. For alcohol use disorder, that evidence may arrive first: multiple phase 2 and phase 3 trials are running, with results expected in 2026-2027.

For alcohol use disorder, that evidence may arrive first: multiple phase 2 and phase 3 trials are running, with results expected in 2026-2027.

The 50% reduction in drug-related deaths at three years, if it is validated in randomized trials, would be among the most significant pharmacological findings in addiction medicine in a generation. The appropriate response to that number is neither dismissal nor celebration. It is exactly what the field is doing: more trials, larger samples, longer follow-ups. The mechanism is plausible, the signal is consistent, and the stakes are high enough that getting the answer right matters more than getting it fast.